Search | Clinical Trials Finder

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1585–1608 of 22,020 matching trials from the local directory fallback.

Filters: Recruiting Clear all

Conditions: Cirrhosis, Decision Support Systems, Clinical
Interventions: CirrhosisRx CDS; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 2,106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Psychiatric Disorder
Interventions: Ketamine Hydrochloride; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: PAD, Peripheral Artery Calcification, Peripheral Artery Disease, Peripheral Artery Stenosis
Interventions: Thor laser atherectomy; Device
Lead sponsor: Philips Clinical & Medical Affairs Global; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 29
States / cities: St. Helena, California • Aurora, Colorado • Bradenton, Florida + 24 more

Conditions: Disease Sickle Cell Anemia, Hb-SS Disease, Hemoglobin S, Sickle Cell Disease, Sickle Cell Disorders
Interventions: Fostamatinib; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Extensive Stage Small Cell Lung Cancer, Limited Stage Small-Cell Lung Cancer, SCLC, Small Cell Lung Cancer
Interventions: Carboplatin or Cisplatin, Durvalumab, Etoposide, Monalizumab; Drug
Lead sponsor: Khalil Choucair; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 4
States / cities: Indianapolis, Indiana • Iowa City, Iowa • Detroit, Michigan + 1 more

Conditions: Postpartum Hypertension
Interventions: Community Health Model (CHM), Remote Medical Model (RMM), SoC; Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 6,030 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: New Haven, Connecticut • Worcester, Massachusetts • Buffalo, New York

Conditions: Large Cell Lymphoma, Diffuse, Refractory Cancer, Relapsed Cancer
Interventions: AutoSCT OR CAR T-cell Therapy, Epcoritamab, GDP; Procedure · Drug
Lead sponsor: Vijendra Singh; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 4
States / cities: Indianapolis, Indiana • Detroit, Michigan • Dallas, Texas + 1 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Carboplatin, Cisplatin, Divarasib, Pembrolizumab, Pemetrexed; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 16
States / cities: Duarte, California • Huntington Beach, California • Irvine, California + 12 more

Conditions: Hypoxic-Ischemic Encephalopathy
Interventions: Placebo, RLS-0071; Drug
Lead sponsor: ReAlta Life Sciences, Inc.; Industry
Eligibility: Up to 10 Hours
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 22
States / cities: Little Rock, Arkansas • Orange, California • San Diego, California + 17 more

Conditions: Ewing Sarcoma, Refractory Ewing Sarcoma, Relapsed Ewing Sarcoma
Interventions: Lurbinectedin; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 2 Years to 30 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 15
States / cities: Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 12 more

Conditions: Colorectal Carcinoma
Interventions: Electronic Health Record Review, Internet-Based Intervention, Interview, Survey Administration; Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Cancer
Interventions: Portal with Virtual Community Health Educator (vCHE), Stand-alone Research Portal; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 100 Years
Enrollment: 350 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Gainesville, Florida • Jacksonville, Florida • Miami, Florida

Conditions: Osteoarthritis, Knee
Interventions: ITIS diet; Dietary Supplement
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Mature B-Cell Non-Hodgkin Lymphoma
Interventions: Carboplatin, Etoposide, Glofitamab, Ifosfamide, Obinutuzumab, Rituximab, Tocilizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 6 Months to 30 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 10
States / cities: Birmingham, Alabama • Oakland, California • Roseville, California + 6 more

Conditions: Diabetes Mellitus, Type 2, Food Deprivation, Nutrition Poor
Interventions: Mid-Ohio Food Farmacy, Mid-Ohio Food Farmacy + Cooking for Diabetes, Mid-Ohio Food Farmacy + Cooking for Diabetes + Health Impact Ohio Pathways Hub, Mid-Ohio Food Farmacy + Health Impact Ohio Pathways Hub; Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 568 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Colorectal Cancer, Lynch Syndrome, T Cells
Interventions: Aspirin, Naproxen; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Solid Tumors
Interventions: Chemotherapy drug, ORIC-114; Drug
Lead sponsor: ORIC Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 17
States / cities: Duarte, California • Huntington Beach, California • Irvine, California + 14 more

Conditions: Trigeminal Neuralgia
Interventions: Trigeminal Electrophysiology; Procedure
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Thyroid Gland Carcinoma
Interventions: Diagnostic Procedure, Electronic Health Record Review, Needle Biopsy; Procedure · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 1,450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Sezary Syndrome
Interventions: Extracorporeal photopheresis (ECP), Methoxsalen Injection; Device · Drug
Lead sponsor: Oleg E. Akilov, MD, PhD; Other
Eligibility: 18 Years to 100 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 3
States / cities: Atlanta, Georgia • Baltimore, Maryland • Pittsburgh, Pennsylvania

Conditions: Multiple Myeloma
Interventions: Bortezomib, Carfilzomib, Cemiplimab, Cevostamab, Daratumumab, Fianlimab, Isatuximab, Lenalidomide, Linvoseltamab, Nirogacestat, Pomalidomide; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 317 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 13
States / cities: La Jolla, California • Atlanta, Georgia • Indianapolis, Indiana + 9 more

Conditions: Pancreatic Ductal Adenocarcinoma
Interventions: Folfirinox, Pembrolizumab; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 3
States / cities: Houston, Texas

Conditions: Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Interventions: Mosunetuzumab, Rituximab, Tocilizumab, Venetoclax; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 5
States / cities: Rochester, Minnesota • New York, New York • Columbus, Ohio + 2 more

Conditions: Pediatric Obstructive Sleep Apnea
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 3 Years to 12 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

CirrhosisRx CDS System

HNC: Human Neural Circuits Electrophysiology During Cognition

The THOR IDE Study

Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease

MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer

Trauma-informed Approach to Timely Detection and Management of Early Postpartum Hypertension

Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma

A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RLS-0071 in Newborns With Moderate or Severe Hypoxic-Ischemic Encephalopathy Undergoing Therapeutic Hypothermia

Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma

A Web-Based Dyadic Intervention for Colorectal Cancer

A Multilevel Approach to Connecting Underrepresented Populations to Clinical Trials

Effect of Anti-inflammatory (ITIS) Diet in Knee Osteoarthritis

A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

Linking Education, Produce Provision, and Community Referrals to Improve Diabetes Care (LINK)

A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

Trigeminal Neuralgia Electrophysiology

Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules

Extracorporeal Photopheresis in Sezary Syndrome

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

Development of a Wearable Point of Care Monitoring Device for Pediatric Obstructive Sleep Apnea